Prescribing medicine today is based on a One Size Fits All principle. We have, however, a need for more personalized solutions in several critical therapy areas. The recent development within genomics and diagnostic field has enabled development of new innovative medicinal products relying on a combination of diagnostic tools and personalized dose. This approach is paving the way towards future health care system based on personalized medicines. Limited attention has been given to the personalized end-product requirements for optimal therapeutic performance. Complex dosing regimens will require advances in product design to enable precise administration of the most appropriate dose. Innovations in pharmaceutical product design are required to alleviate potential problems.
Pharmaceutical sciences is a broad area covering biology, chemistry and physics, as well as engineering disciplines. Nordic POP (patient oriented products) is aiming at providing the scientific foundation for the next generation pharmaceutical products by strengthening the use of interdisciplinary approaches within Nordic pharmaceutical sciences. More specifically, this proposal will deliver innovative patient oriented products; our approach is including new product design principles, novel methods for better understanding of the product performance, and a paradigm shift in the manufacturing of these products. With this approach, new type of personalized treatment strategies can be designed and the individual variation between patients can be taken into account.
Nordic POP will focus on publishing all the research findings in high impact scientific journals according to a research dissemination plan. This project will focus on mentoring younger scientists and aim for at least two new European Research Council (ERC) grants from this consortium. It is expected that Nordic POP will position this network in an absolute leading position in Europe within pharmaceutical sciences. At the educational level, the mobility of PhD students and senior staff in the HUB will be forming a basis for shared teaching activities. Additionally, innovation and entrepreneurship will be in an active focus of the network this proposal will form a basis for new startup companies. Finally, industrial dissemination will be an important part of the network activities with a specific goal of safeguarding the strong global position of Nordic pharmaceutical companies.
